PSMB5 and Miyoshi myopathy: Our data demonstrate that in MM miR-155, in contrast with other types of cancers where it acts as onco-miRNA, exerts a protective role against tumorigenesis and alleviates bortezomib resistance, likely via PSMβ5 targeting.